Search company, investor...

Predict your next investment

GMS Holdings company logo
Holding Company
FINANCE | Investment Firms & Funds
gmsholdings.com

Investments

3

Partners & Customers

2

About GMS Holdings

GMS Holdings is a holding company for a group of diversified businesses and assets around the world. The company's investments span several geographies and industries in both the private and public domains. The company operates through three main subsidiaries, which are GMS Specialized Services, GMS Ventures & Investments and GMS Real Estate.

Headquarters Location

7th Circle Zahran Plaza Building, 4th Floor Zahran Street

Amman, 11844,

Jordan

+962 6 5827999

Want to inform investors similar to GMS Holdings about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest GMS Holdings News

BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics

Apr 22, 2022

Iselin, New Jersey, UNITED STATES SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and BioLexis Pte Ltd. (“BioLexis”), a strategic shareholder in Outlook Therapeutics, today announced that BioLexis is being reorganized. The BioLexis reorganization, which does not entail any changes in the indirect ownership of Outlook Therapeutics, provides GMS Holdings with increased flexibility to support the future growth of Outlook Therapeutics as its largest shareholder. Pursuant to an agreement among BioLexis, GMS Ventures & Investments (“GMS V&I”), and certain of GMS V&I’s affiliates (GMS V&I and its affiliates, “GMS Holdings”), on April 21, 2022, GMS V&I has taken direct ownership of all of the shares of Outlook Therapeutics that were indirectly owned by GMS Holdings through BioLexis. As the next step in the reorganization, GMS Holdings will cease to be a shareholder in BioLexis and BioLexis will be renamed “Tenshi Healthcare Pte Limited” (or such other name as may be approved by the regulatory authorities in Singapore). GMS Holdings does not have an economic interest in, or voting rights with respect to, the shares of Outlook Therapeutics that are held by BioLexis. BioLexis directly holds the shares beneficially owned by the minority shareholder in BioLexis, Tenshi Life Sciences Private Limited and Tenshi Life Sciences Pte Limited. Since the initial investment by BioLexis in 2017, Outlook Therapeutics has undergone a significant transformation and has successfully completed three clinical trials which recently culminated in a BLA submission to the U.S. FDA on March 30, 2022. As the largest investor, GMS Holdings actively supported Outlook Therapeutics by leading and participating in multiple capital raises to support the Outlook Therapeutics growth strategy. “The submission of a Biologics License Application (BLA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) with FDA is a significant milestone to achieve and places Outlook Therapeutics on a path to potential marketing approval for a very promising therapy,” said Faisal Sukhtian, Executive Director of GMS Holdings and a member of the Board of Directors of BioLexis. “With this milestone accomplished, the shareholders of BioLexis have fully realized their intended objectives for the joint venture. This reorganization will see the existing partners translate their joint ownership positions in Outlook Therapeutics into direct stakes.” “We appreciate the longstanding support we have received from BioLexis and look forward to executing on our priorities to create value for all shareholders,” added Russell Trenary, President and CEO of Outlook Therapeutics. In connection with the reorganization, Outlook Therapeutics and GMS Holdings entered into an Amended and Restated Investor Rights Agreement, which replaces the previous Investor Rights Agreement among Outlook Therapeutics, BioLexis and GMS V&I. BioLexis no longer has any rights under the Amended and Restated Investor Rights Agreement. About Outlook Therapeutics, Inc. Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational therapy, as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD. The submission is supported by Outlook Therapeutics’ wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit  www.outlooktherapeutics.com . About GMS Holdings GMS Holdings is a holding company for a group of diversified businesses and assets around the world. Investments span several geographies and industries in both the private and public domains. With a long track record of building successful organizations which are market leaders in the fields in which they operate, GMS Holdings makes investments with a global perspective, and is driven by a firm belief that superior results are achieved through a commitment to long term growth. CONTACTS:

GMS Holdings Investments

3 Investments

GMS Holdings has made 3 investments. Their latest investment was in Wafii as part of their Seed on October 10, 2022.

CBI Logo

GMS Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/11/2022

Seed

Wafii

Yes

GMS Holdings, and Undisclosed Angel Investors

2

3/19/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2017

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/11/2022

3/19/2021

10/16/2017

Round

Seed

Series C

Unattributed

Company

Wafii

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

GMS Holdings, and Undisclosed Angel Investors

Sources

2

10

10

GMS Holdings Partners & Customers

2 Partners and customers

GMS Holdings has 2 strategic partners and customers. GMS Holdings recently partnered with Outlook Therapeutics on March 3, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

3/30/2022

Partner

United States

Outlook Therapeutics Inc says BioLexis reorganization results in GMS Holdings becoming its largest shareholder

In connection with the reorganization , Outlook Therapeutics and GMS Holdings forged an Amended and Restated Investor Rights agreement , which replaces the previous Investor Rights Agreement among Outlook Therapeutics , BioLexis and GMS V&I .

1

9/8/2017

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

3/30/2022

9/8/2017

Type

Partner

Licensor

Business Partner

Country

United States

United States

News Snippet

Outlook Therapeutics Inc says BioLexis reorganization results in GMS Holdings becoming its largest shareholder

In connection with the reorganization , Outlook Therapeutics and GMS Holdings forged an Amended and Restated Investor Rights agreement , which replaces the previous Investor Rights Agreement among Outlook Therapeutics , BioLexis and GMS V&I .

Subscribe to see more

Subscribe to see more

Sources

1

10

GMS Holdings Team

2 Team Members

GMS Holdings has 2 team members, including , .

Name

Work History

Title

Status

Ghiath Sukhtian

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Ghiath Sukhtian

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.